ABSORB Post-Approval Clinical Study

The ABSORB Post-Approval Clinical Study is a prospective, open-label, multi-center, single-arm, non-randomized trial to evaluate the safety of the use of ABSORB in a real-world setting following commercial physician training'and to observe the effectiveness of commercial physician training on appropriate vessel sizing.

Study Overview

• Status: Withdrawn
• Conditions: Ischemic Heart Disease
• Intervention / Treatment: Device: Absorb BVS

Detailed Description

After approval of commercial use of Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System in over 75 countries as of December 31, 2015, Abbott Vascular has developed a post-approval commitment plan that includes the initiation of the ABSORB Post-Approval Clinical Study, a single-arm trial that will include approximately 2000 subjects at approximately 265 sites in the US and Canada.

The objectives of ABSORB PostApproval Study are the following:

• Evaluate the safety of the use of Absorb in a real world setting following commercial physician training.
• Observe the effectiveness of commercial physician training on appropriate vessel sizing in the use of Absorb in a real world setting.

The study design allows evaluating low frequency events, effectiveness of commercial physician training and education for very small vessels (< 2.25 mm as assessed by quantitative coronary angiography [QCA]), and confirmation of generalizability of the treatment with Absorb to real-world practice. The estimated follow-up of safety and effectiveness will be 3 years.

Angiographic Subgroup:

Approximately the first 500 consecutive subjects implanted by operators inexperienced in the usage of Absorb GT1 BVS to receive baseline assessment of reference vessel diameter (RVD) by the angiographic core laboratory. An inexperienced operator is defined as having performed two or fewer Absorb implants prior to commercial approval. The purpose of the angiographic subgroup is to evaluate the effectiveness of training in the selection of appropriately sized coronary arteries for GT1 BVS implantation. Study staff will be notified after the procedure if the subject is in the angiographic subgroup, and instructed to send pre-procedure angiogram and supporting materials to core laboratory for assessment.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Tallahassee, Florida, United States, 32308
      • Tallahassee Memorial Hospital
  • Indiana
    • Indianapolis, Indiana, United States, 46237
      • Franciscan St. Francis Health
  • Kentucky
    • Louisville, Kentucky, United States, 40207
      • Baptist Health Louisville
  • New Jersey
    • Englewood, New Jersey, United States, 07631
      • Englewood Hospital and Medical Center
  • Tennessee
    • Knoxville, Tennessee, United States, 37934
      • Turkey Creek Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The subject agrees and signs the Institutional Review Board (IRB) approved informed consent form
• The subject receives an Absorb

Exclusion Criteria:

• Subject is a member of a vulnerable population.

Vulnerable population: Defined as subject whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate. Examples of populations which may contain vulnerable subjects include: Individuals with lack of or loss of autonomy due to immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for example, members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces, and persons kept in detention

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: Absorb BVS; Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).

Device: Absorb BVS; Commercially approved Absorb GT1 BVS, herein referred to as "Absorb".; Scaffold diameters: 2.5, 3.0, and 3.5 mm; Scaffold lengths: 8, 12, 18, 23 and 28 mm Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite of cardiac death, myocardial infarction (CD/MI)	Myocardial infarction will be assessed per the Universal MI definition.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Definite/probable scaffold thrombosis (ST)	ST is assessed per the Academic Research Consortium (ARC) definite/probable definition.	1 year
The annual rate of definite/probable scaffold thrombosis	ST is assessed per the Academic Research Consortium (ARC) definite/probable definition.	At 1 year post-index procedure
The annual rate of definite/probable scaffold thrombosis	ST is assessed per the Academic Research Consortium (ARC) definite/probable definition.	Between 1 year and 2 years (366 to 730 days) post index procedure
The annual rate of definite/probable scaffold thrombosis	ST is assessed per the Academic Research Consortium (ARC) definite/probable definition.	Between 2 years and 3 years (731 to 1095 days) post index procedure
Percentage of very small vessels (per-lesion basis)	This is the commercial Training Assessment Endpoint (Angiographic Subgroup only). Pre-procedure reference vessel diameter (RVD) < 2.25 mm as assessed by core laboratory using quantitative coronary angiography (QCA).	Pre-procedure (on day 0)
Death (Cardiac, Non-Cardiac)	Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	≤ 7 days post index procedure (In-hospital )
Death (Cardiac, Non-Cardiac)		30 days
Death (Cardiac, Non-Cardiac)		180 days
Death (Cardiac, Non-Cardiac)		1 year
Death (Cardiac, Non-Cardiac)		2 years
Death (Cardiac, Non-Cardiac)		3 years
All Myocardial Infarction (All MI)		≤ 7 days post index procedure (In-hospital )
All Myocardial Infarction (All MI)		30 days
All Myocardial Infarction (All MI)		180 days
All Myocardial Infarction (All MI)		1 year
All Myocardial Infarction (All MI)		2 years
All Myocardial Infarction (All MI)		3 years
Target Lesion Revascularization (TLR)	TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.	≤ 7 days post index procedure (In-hospital )
Target Lesion Revascularization (TLR)		30 days
Target Lesion Revascularization (TLR)		180 days
Target Lesion Revascularization (TLR)		1 year
Target Lesion Revascularization (TLR)		2 years
Target Lesion Revascularization (TLR)		3 years
Ischemia Driven TLR (ID-TLR)	TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.	≤ 7 days post index procedure (In-hospital )
Ischemia Driven TLR (ID-TLR)		30 days
Ischemia Driven TLR (ID-TLR)		180 days
Ischemia Driven TLR (ID-TLR)		1 year
Ischemia Driven TLR (ID-TLR)		2 years
Ischemia Driven TLR (ID-TLR)		3 years
Target Vessel Revascularization (TVR)	TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	≤ 7 days post index procedure (In-hospital )
Target Vessel Revascularization (TVR)		30 days
Target Vessel Revascularization (TVR)		180 days
Target Vessel Revascularization (TVR)		1 year
Target Vessel Revascularization (TVR)		2 years
Target Vessel Revascularization (TVR)		3 years
All coronary revascularization		≤ 7 days post index procedure (In-hospital )
All coronary revascularization		30 days
All coronary revascularization		180 days
All coronary revascularization		1 year
All coronary revascularization		2 years
All coronary revascularization		3 years
Scaffold thrombosis (per ARC definition)	Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab. Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: >1 year post stent implantation	Acute (0 - 24 hours post stent implantation) (Definite and Probable)
Scaffold thrombosis (per ARC definition)		Subacute (>24 hours - 30 days post stent implantation)(Definite and Probable)
Scaffold thrombosis (per ARC definition)		Late (30 days - 1 year post stent implantation) (Definite and Probable)
Scaffold thrombosis (per ARC definition)		Very late (>1 year post stent implantation) (Definite and Probable)
Death/All Myocardial Infarction (MI)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.	≤ 7 days post index procedure (In-hospital )
Death/All Myocardial Infarction (MI)		30 days
Death/All Myocardial Infarction (MI)		180 days
Death/All Myocardial Infarction (MI)		1 year
Death/All Myocardial Infarction (MI)		2 years
Death/All Myocardial Infarction (MI)		3 years
Cardiac Death/All Myocardial Infarction (MI)	Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.	≤ 7 days post index procedure (In-hospital )
Cardiac Death/All Myocardial Infarction (MI)		30 days
Cardiac Death/All Myocardial Infarction (MI)		180 days
Cardiac Death/All Myocardial Infarction (MI)		1 year
Cardiac Death/All Myocardial Infarction (MI)		2 years
Cardiac Death/All Myocardial Infarction (MI)		3 years
Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [Target vessel failure;TVF]		≤ 7 days post index procedure (In-hospital )
Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [TVF]		30 days
Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [TVF]		180 days
Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [TVF]		1 year
Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [TVF]		2 years
Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [TVF]		3 years
Cardiac Death/TV MI/ID-TLR (Target lesion failure;TLF)		≤ 7 days post index procedure (In-hospital )
Cardiac Death/TV MI/ID-TLR (TLF)		30 days
Cardiac Death/TV MI/ID-TLR (TLF)		180 days
Cardiac Death/TV MI/ID-TLR (TLF)		1 year
Cardiac Death/TV MI/ID-TLR (TLF)		2 years
Cardiac Death/TV MI/ID-TLR (TLF)		3 years
Death/All Myocardial Infarction (MI)/All revascularization		≤ 7 days post index procedure (In-hospital )
Death/All Myocardial Infarction (MI)/All revascularization		30 days
Death/All Myocardial Infarction (MI)/All revascularization		180 days
Death/All Myocardial Infarction (MI)/All revascularization		1 year
Death/All Myocardial Infarction (MI)/All revascularization		2 years
Death/All Myocardial Infarction (MI)/All revascularization		3 years

Collaborators and Investigators

• Sponsor: Abbott Medical Devices
• Investigators: Study Director: Peter Staehr, Abbott Medical Devices

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): August 1, 2017
• Primary Completion (ANTICIPATED): December 1, 2018
• Study Completion (ANTICIPATED): January 1, 2021

Study Registration Dates

• First Submitted: October 19, 2016
• First Submitted That Met QC Criteria: October 21, 2016
• First Posted (ESTIMATE): October 25, 2016

Study Record Updates

• Last Update Posted (ACTUAL): January 11, 2018
• Last Update Submitted That Met QC Criteria: January 9, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Keywords: Stents; Myocardial ischemia; Stent thrombosis; Bioabsorbable; BVS; Absorb GT1 BVS
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Heart Diseases; Coronary Artery Disease; Myocardial Ischemia
• Other Study ID Numbers: 15-307

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes